|
Home | Current Issue |
Past
Issues | Search | Collections
| PDA Services | Subscribe | Contact Us | Help | ACP Online
|
1 June 1999 | Volume 130 Issue 11 | Page 944
A 44-year-old woman was seen for acute hepatitis on 23 March 1998. Results of liver function tests done in September 1997 at the time of the introduction of venlafaxine therapy (150 mg/d) were normal. For several months the patient had also been taking lormetazepam and trazodone for her depression. She had undergone hysterectomy in 1996 for a fibroma. On 9 March 1998, blood tests were performed by her general practitioner because of severe asthenia. Findings included an alanine aminotransferase level of 1082 U/L (normal, <56 U/L) and an aspartate aminotransferase level of 661 U/L (normal, <40 U/L).
When the patient was seen in our institution on 30 March, a similar perturbation in liver function test results was observed. Results of serologic tests for hepatitis, iron studies, antimitochondrial, and anti-smooth-muscle antibodies were normal or negative. Abdominal ultrasonography showed no abnormalities. Examination of a percutaneous liver biopsy specimen obtained on 9 April revealed well-demarcated zone 3 confluent necrosis, with some inflammation and clumps of perivenular Kupffer cells containing lipid-rich ceroid pigment. The portal tracts were unaffected (Figure ). Venlafaxine therapy was then progressively discontinued because of the risk for withdrawal symptoms (3). The patient continued to receive lormetazepam and trazodone. Liver function test results progressively improved and returned to normal 4 months after discontinuation of venlafaxine therapy. The result of a second serologic test for hepatitis C performed in July 1998 was also negative.
|
We believe that there was a causal association between venlafaxine and hepatitis because the histologic findings supported drug-related hepatotoxicity, other causes of hepatitis were excluded, discontinuation of venlafaxine therapy led to recovery, and venlafaxine can increase liver aminotransferase levels. Liver function test results should therefore be regularly monitored in patients receiving venlafaxine.
Author
and Article Information
|
---|
Top Author & Article Info References |
---|
References
|
---|
Top Author & Article Info References |
---|
1. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995;49:280-94.[Medline]
2. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother. 1995;29:387-95.[Medline]
3. Johnson H, Bouman WP, Lawton J. Withdrawal
reaction associated with venlafaxine. BMJ. 1998;317:787-787.
About Letters
The Editors welcome submissions for possible publication in
the Letters section. Authors of letters should:
Include no more than 300 words of text, three
authors, and five references
Type with
double-spacing
Send three copies of the
letter, an authors' form (see Table of Contents for location) signed by all
authors, and a cover letter describing any conflicts of interest related to the
contents of the letter
Letters commenting
on an Annals article will be considered if they are received within 6 weeks of
the time the article was published. Only some of the letters received can be
published. Published letters are edited and may be shortened; tables and figures
are included only selectively. Authors will be notified that the letter has been
received. If the letter is selected for publication, the author will be notified
about 3 weeks before the publication date. Unpublished letters cannot be
returned.
Annals welcomes electronically
submitted letters. The Internet address is http://www.acponline.org/journals/annals/letters.
This article has been cited by other articles:
I. Sencan, I. Sahin, and A. Ozcetin Low-dose venlafaxine-associated liver toxicity in chronic hepatitis Ann. Pharmacother., February 1, 2004; 38(2): 352 - 353. [Full Text] [PDF] |
|||||
|
X. Cardona, A. Avila, and P. Castellanos Venlafaxine-Associated Hepatitis Ann Intern Med, March 7, 2000; 132(5): 417 - 417. [Full Text] [PDF] |
|||||
|
|